Treatment of Advanced Carcinoma of the Prostate (Stage D) with Infusion of CIS-Diamminedichloroplatinum (II NSC 119875): A Pilot Study

Abstract

A study was done in 21 patients who had advanced carcinoma of the prostate (stage D) treated with 1 mg/kg cis-diamminedichloroplatinum/week for 6 wk. The infusions were spaced every 3 wk thereafter. One patient was never treated previously and 20 patients were failures of previous therapy with estrogens and/or radiotherapy and/or chemotherapy. A partial objective clinical remission was seen in 9 of the 21 patients (43%). This response lasted 3-14 mo., with an average of 5.8 mo. The responses were evidenced by a 50% or more decrease of lesions in the liver (2 patients), recalcification of a bone lytic lesion (1 patient), disappearance of positive lymph nodes in the neck (2 patients), disappearance of pleural effusion (1 patient), disappearance of lymphatic block of lower extremities (2 patients) and disappearance of lung metastases and ureteral obstruction (1 patient). Six patients (28.5%) had a complete disappearance of bone pain and became ambulatory and asymptomatic, 2 patients (9.5%) with bony metastases remained asymptomatic and apparently stable and 4 patients did not respond to treatment and showed progression. cis-Diamminedichloroplatinum seems to be the most effective drug available to date for the treatment of advanced carcinoma of the prostate.